We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. Click on one of the therapeutic category icons below to learn how our revolutionary technology is helping researchers advance the science of precision health.
SIMOA HD-1 Analyzer
This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Kevin Hrusovsky, Quanterix Chairman and CEO and Founder of Powering Precision Health, recently sat down with TetraScience CEO Alok Tayi to talk about the exciting work that Quanterix is doing in the area of clinical biomarkers and the business of diagnostics as well as a broader view of healthcare in the United States.
Quanterix' proprietary Simoa™ technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.
We're passionate about the work we do and believe we can transform today’s sick care into tomorrow’s precision healthcare. The future of healthy living is being realized by uncovering novel biomarkers with the power to transform medicine, allowing for prevention, early diagnosis and nextgen treatments.
According to the Centers for Disease Control, up to four million concussions occur each year. A big challenge is trying to figure out whether someone has actually had one or not. Lexington-based Quanterix may have a solution.
“It’s like rocket science on the blood,” says Quanterix CEO and Executive Chairman, Kevin Hrusovsky.
Read the full report on boston.cbslocal.com
In an excerpt from a panel discussion which took place at MedCity CONVERGE on July 11, 2018, Quanterix Chairman and CEO Kevin Hrusovsky joins other key innovators to discuss game-changing biotech advancements and the future of healthcare.